During the past decade, Azienda Ospedaliera S. Maria di Terni conducted 79 clinical trials. In the 10-year time frame, 79 clinical trials started and 26 clinical trials were completed, i.e. on average, 32.9% percent of trials that started reached the finish line to date. In the past 5 years, 38 clinical trials started and 24 clinical trials were completed. i.e. 63.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Ospedaliera S. Maria di Terni" #1 sponsor was "Fondazione Italiana Linfomi ONLUS" with 8 trials, followed by "Celgene" with 6 trials sponsored, "BeiGene" with 4 trials sponsored, "Janssen Research & Development, LLC" with 4 trials sponsored and "Pfizer" with 4 trials sponsored. Other sponsors include 71 different institutions and companies that sponsored additional 55 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliera S. Maria di Terni" #1 collaborator was "Clinical Research Technology S.r.l." with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Foundation Medicine" with 2 trials as a collaborator, "ALS Association" with 1 trials as a collaborator and "AbbVie" with 1 trials as a collaborator. Other collaborators include 28 different institutions and companies that were collaborators in the rest 38 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliera S. Maria di Terni" are "Multiple Myeloma" (11 trials), "Breast Cancer" (5 trials), "Prostatic Neoplasms" (4 trials), "Chronic Lymphocytic Leukemia" (3 trials) and "Follicular Lymphoma" (3 trials). Many other conditions were trialed in "Azienda Ospedaliera S. Maria di Terni" in a lesser frequency.

Most popular intervention types in "Azienda Ospedaliera S. Maria di Terni" are "Drug" (89 trials), "Other" (13 trials), "Biological" (9 trials), "Procedure" (4 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Dexamethasone" (7 trials), "Rituximab" (5 trials), "Avelumab" (4 trials) and "Pomalidomide" (4 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Ospedaliera S. Maria di Terni" are 90 trials for "All" genders, 9 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Azienda Ospedaliera S. Maria di Terni". undefined are not yet recruiting, 23 are recruiting, 23 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 38 completed trials in Azienda Ospedaliera S. Maria di Terni, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Ospedaliera S. Maria di Terni, 4 "Phase 1" clinical trials were conducted, 34 "Phase 2" clinical trials and 49 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".

Azienda Ospedaliera S. Maria di Terni has several departments that took part in Clinical trials: "A.O. Santa Maria - Terni S.C Oncoematologia" - 28 trials, "SS.C. di Oncoematologia - Dipartimento di Medicina Clinica e Sperimentale - Azienda Ospedaliera - S. Maria Di Terni" - 8 trials, "Azienda Ospedaliera Santa Maria, S.C. Di Cardiologia" - 4 trials, "Az. Osp. S. Maria; Dept. Di Oncologia Medica" - 4 trials